UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 24, 2011

NOBLE MEDICAL TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Delaware		333-150483		20-0587718
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4751 Wilshire Boulevard, 3rd Floor, Los Angeles, CA		90010
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (310) 601-2500

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 1.01

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On January 24, 2011, Noble Medical Technologies, Inc. (the "Company") entered into a Securities Purchase Agreement (“Securities Purchase Agreement”) pursuant to which the Company issued a Senior Promissory Note for $50,000 principal amount ("Note") and a 10 year common stock warrant to purchase 166,666 shares of the Company's common stock at an exercise price of $0.10 per share ("Warrant"). The Note matures on January 23, 2012, and is subject to interest at an annual rate of 10%. The Warrant vests over a period of one year, 20% on February 1, 2011 and 80% on January 1, 2012. The vesting of the Warrant will accelerate to 100% upon a Liquidity Event or Funding Event as defined in the Warrant. The Securities Purchase Agreement, the Note and the Warrant are attached as exhibits to this report and incorporated herein by reference.

ITEM 3.02

UNREGISTERED SALES OF EQUITY SECURITIES

On January 24, 2011, Noble Medical Technologies, Inc. (the "Company") entered into a Securities Purchase Agreement (“Securities Purchase Agreement”) pursuant to which the Company issued a Senior Promissory Note for $50,000 principal amount ("Note") and a 10 year common stock warrant to purchase 166,666 shares of the Company's common stock at an exercise price of $0.10 per share ("Warrant"). The Note matures on January 23, 2012, and is subject to interest at an annual rate of 10%. The Warrant vests 20% on February 1, 2011 and 80% on January 1, 2012. The vesting of the Warrant will accelerate to 100% upon a Liquidity Event or Funding Event as defined in the Warrant. The Securities Purchase Agreement, the Note and the Warrant are attached as exhibits to this report and incorporated herein by reference. The Note and Warrant were issued without registration under the Securities Act of 1933, as amended, ("1933 Act") pursuant to the exemption from registration afforded by Section 4(2) of the 1933 Act. No selling commission or placement agent fees were paid by the Company in connection with the transaction.

ITEM 9.01

FINANCIAL STATEMENT AND EXHIBITS.

(D)	Exhibits.

	10.1	Securities Purchase Agreement, dated January 24, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NOBLE MEDICAL TECHNOLOGIES, INC.

DATED: January 24, 2011	By:	/s/ Tatiana Walker
		Tatiana Walker
		Secretary

INDEX TO EXHIBITS

	EXHIBIT NO.		DESCRIPTION OF EXHIBIT

	10.1		Securities Purchase Agreement, dated January 24, 2011

Noble Medical Technologies, Inc. 8-K